Key result
Rivaroxaban was associated with a similar risk of VTE recurrence and bleeding compared to dalteparin in patients with lung cancer.
Why the study?
Although direct oral anticoagulant use has increased for cancer-associated VTE, their efficacy and safety specifically in lung cancer patients remain unclear.
Does rivaroxaban improve the composite of VTE recurrence and bleeding compared to dalteparin in patients with primary lung cancer and VTE?
Cohort (n=204)
No
Does rivaroxaban improve the composite of VTE recurrence and bleeding compared to dalteparin in patients with primary lung cancer and VTE?
Rivaroxaban demonstrated a similar safety and efficacy profile to dalteparin for the treatment of VTE in patients with primary lung cancer, suggesting it is a viable alternative.
Answers are grounded in this paper and cite their sources.
Supports rivaroxaban as potential alternative in lung cancer VTE; leaves open need for randomized confirmation.
BACKGROUND: Standard therapy for cancer-associated venous thromboembolism (VTE) is low-molecular-weight heparin. The use of direct oral anticoagulants for cancer-associated VTE has increased; however, their efficacy and safety in lung cancer patients remain unclear. OBJECTIVES: We examined the efficacy and safety of rivaroxaban compared with dalteparin for cancer-associated VTE in patients with primary lung cancer. METHODS: A single-center retrospective study of 204 patients with primary lung cancer who were prescribed rivaroxaban (n = 131) or dalteparin (n = 73) for VTE was performed. The primary endpoint was a composite event including recurrence and major or clinically relevant nonmajor bleeding. Secondary endpoints included the incidence of recurrence, major and clinically relevant nonmajor bleeding, all-cause mortality, and bleeding or pulmonary embolism-related mortality. RESULTS: The composite event occurred in 38 (29.0) and 12 (16.4%) patients in the rivaroxaban and dalteparin (p = 0.045) groups, respectively. The multivariate Cox proportional hazards model for age, Eastern Cooperative Oncology Group performance score, and bleeding risk factors revealed the rivaroxaban group showed a 1.176-fold composite event risk without statistical significance (0.595-2.324, p = 0.641). There was no statistically significant intergroup difference for the incidence of VTE recurrence (5.3% in the rivaroxaban group versus 2.7% in the dalteparin group, p = 0.495) and major or clinically relevant nonmajor bleeding (23.7% in the rivaroxaban group versus 13.7% in the dalteparin group, p = 0.089). There was no significant difference in the all-cause mortality rate (hazard ratio 0.864, 95% CI 0.624-1.196, p = 0.337). CONCLUSIONS: There was no difference in the safety and efficacy profile of rivaroxaban compared with dalteparin. Therefore, rivaroxaban may be a valuable treatment option for lung cancer-associated VTE.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2019) conducted a cohort in Venous thromboembolism in primary lung cancer (n=204). Rivaroxaban vs. Dalteparin was evaluated on Composite event including VTE recurrence and major or clinically relevant nonmajor bleeding (HR 1.176, 95% CI 0.595-2.324, p=0.641). Rivaroxaban was associated with a similar risk of VTE recurrence and bleeding compared to dalteparin in patients with lung cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: